Zacks Small Cap Brokers Cut Earnings Estimates for Revelation Biosciences, Inc. (NASDAQ:REVB)

Revelation Biosciences, Inc. (NASDAQ:REVBFree Report) – Analysts at Zacks Small Cap cut their Q1 2024 earnings per share (EPS) estimates for Revelation Biosciences in a note issued to investors on Monday, March 25th. Zacks Small Cap analyst B. Sorensen now expects that the company will post earnings per share of ($9.00) for the quarter, down from their prior forecast of ($7.51). The consensus estimate for Revelation Biosciences’ current full-year earnings is ($20.77) per share. Zacks Small Cap also issued estimates for Revelation Biosciences’ Q2 2024 earnings at ($9.00) EPS, Q3 2024 earnings at ($9.00) EPS, Q4 2024 earnings at ($8.70) EPS, FY2024 earnings at ($35.73) EPS, Q1 2025 earnings at ($8.60) EPS, Q2 2025 earnings at ($8.60) EPS, Q3 2025 earnings at ($8.60) EPS, Q4 2025 earnings at ($8.70) EPS and FY2025 earnings at ($34.50) EPS.

Revelation Biosciences Price Performance

NASDAQ REVB opened at $2.43 on Wednesday. Revelation Biosciences has a 1-year low of $2.22 and a 1-year high of $49.80. The business has a 50 day simple moving average of $4.54 and a two-hundred day simple moving average of $13.61. The stock has a market capitalization of $510,300.00, a PE ratio of 0.08 and a beta of 0.14.

Institutional Investors Weigh In On Revelation Biosciences

Large investors have recently bought and sold shares of the business. Ergoteles LLC bought a new stake in shares of Revelation Biosciences in the 1st quarter worth about $25,000. CVI Holdings LLC purchased a new stake in Revelation Biosciences during the first quarter valued at approximately $43,000. State Street Corp bought a new stake in shares of Revelation Biosciences in the 3rd quarter valued at approximately $28,000. Hudson Bay Capital Management LP purchased a new position in shares of Revelation Biosciences in the 1st quarter worth approximately $142,000. Finally, Sabby Management LLC purchased a new position in shares of Revelation Biosciences in the 1st quarter worth approximately $235,000. Institutional investors own 12.80% of the company’s stock.

Revelation Biosciences Company Profile

(Get Free Report)

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease.

Featured Articles

Earnings History and Estimates for Revelation Biosciences (NASDAQ:REVB)

Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.